Oppenheimer Boosts Tyra Biosciences (NASDAQ:TYRA) Price Target to $33.00

Tyra Biosciences (NASDAQ:TYRA) had its price target boosted by Oppenheimer from $25.00 to $33.00 in a research note published on Thursday, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages have also weighed in on TYRA. HC Wainwright restated a buy rating and issued a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Wedbush reissued an outperform rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Finally, Piper Sandler began coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They set an overweight rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Tyra Biosciences has a consensus rating of Moderate Buy and an average price target of $26.40.

Tyra Biosciences Stock Up 1.5 %

TYRA stock opened at $24.36 on Thursday. Tyra Biosciences has a 52 week low of $10.38 and a 52 week high of $25.14. The firm has a 50-day simple moving average of $21.29 and a 200-day simple moving average of $18.72. The stock has a market capitalization of $1.28 billion, a P/E ratio of -14.50 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, analysts expect that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, CEO Todd Harris sold 5,698 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38. Following the transaction, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Several institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after acquiring an additional 3,180,155 shares during the last quarter. BVF Inc. IL grew its holdings in shares of Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the period. Perceptive Advisors LLC increased its position in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Vanguard Group Inc. raised its holdings in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after buying an additional 140,833 shares during the period. Finally, Kynam Capital Management LP lifted its position in Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock valued at $8,449,000 after buying an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.